MRNA MRNA
Company Analysis
Latest News
Moderna Rallies on Five-Year Cancer Vaccine Data, Pivots Away from Vaccine Development
Moderna and Merck announced positive five-year follow-up data for their personalized mRNA cancer vaccine combined with Keytruda, showing it maintained a 49%...
Moderna Shares Plunge as CEO Halts Funding for New Phase 3 Vaccine Trials
Moderna shares plunged 8.75% to $47.33 after CEO Stéphane Bancel announced the company would not fund new Phase 3 vaccine trials in the foreseeable future,...
🔴 Moderna is trading 3.26% down in pre-market after recent rally pullback
MRNA is trading at $50.18, down 3.26% in pre-market, as the stock experiences profit-taking following a dramatic two-day surge. The initial rally saw the...
Moderna CEO Stephane Bancel Announces Halt to New Late-Stage Vaccine Trial Investment
Moderna announced a major strategic pivot, ceasing investment in new late-stage vaccine trials and instead redirecting capital toward its oncology and heart...
🟢 Moderna is trading 3% up today on continued momentum from cancer vaccine data
MRNA is trading at $51.30 (+2.99%) amid ongoing gains after strong five-year Phase 2b data showed its personalized mRNA cancer therapy combined with Keytruda...
🟢 Moderna is trading 3.3% up in after-hours trading on positive oncology data momentum
MRNA is trading at $51.46 (+3.3%) in after-hours, extending the significant intraday rally (which closed at +15.8%) driven by positive five-year follow-up data...
🟢 Moderna is trading 3.05% up today after five-year cancer vaccine data shows sustained efficacy
MRNA is trading up 3.05% at $44.31 following the announcement of positive five-year follow-up data for its intismeran autogene combined with Keytruda in...
Moderna & Merck Report Sustained Positive 5-Year Data for Personalized Cancer Vaccine
Moderna and Merck announced positive five-year follow-up data from the Phase 2b study of intismeran autogene (mRNA-4157). This investigational personalized...
🟢 Moderna is trading 6% up today after lifting 2025 revenue outlook
MRNA is trading at $41.83 (+6.28%) after raising its 2025 revenue forecast to ~$1.9B and outlining major operating expense cuts. * The company reiterated...
Moderna Gains as European Patent Office Revokes Key Arbutus Patent
Moderna’s stock rose after the Board of Appeal of the European Patent Office revoked a patent held by Arbutus Biopharma. Moderna (MRNA) shares added...
🔴 Moderna is trading 3.04% down today after profit-taking following recent rally
MRNA is trading at $39.34, down 3.04%, representing profit-taking after the dramatic 17.02% surge following upbeat preliminary 2025 results and 2026...
Moderna shares surge 15.60% to $39.12 on raised 2025 revenue forecast and cost cuts
Moderna released an update ahead of the J.P. Morgan Healthcare Conference, raising its 2025 revenue expectation to $1.9 billion and announcing a significant...
🟢 Moderna is trading 3.4% up today
MRNA is trading at $34.98 (+3.4%) amid continued positive momentum following its standalone flu vaccine filing and optimism around oncology data. Recent...
Bayer Sues Moderna Over mRNA Technology in COVID-19 Vaccines
Bayer’s Monsanto division filed a patent infringement lawsuit against Moderna, Pfizer, and BioNTech. The suit alleges the companies misused Monsanto’s...
🟢 MRNA is trading 3% up today on continued momentum from flu vaccine filing
MRNA is trading at $36.89 (+3.45%) following Tuesday's 10.9% surge, driven by the filing for approval of its seasonal flu vaccine (mRNA-1010) in major markets...
Moderna Stock Surges 10%+ on Flu Vaccine Filing, Cost Cuts, and Analyst Upgrade
Moderna's stock surged +10.85% after the company filed for global regulatory approval of its promising mRNA-1010 seasonal flu vaccine, boosting investor...
Moderna Stock Downgraded by UBS on Weak Profit Outlook
UBS analysts downgraded Moderna (MRNA) stock from Buy to Hold. The firm also reduced the price target from $40 to $34. The downgrade stems from concerns over...
🟢 MRNA is trading 5% up today following FDA flu vaccine regulatory submissions
MRNA is trading up 4.99% at $33.77 following Moderna's announcement of regulatory submissions for its seasonal flu vaccine, mRNA-1010. * The company filed...
🟢 MRNA is trading 3.16% up today driven by mRNA-1010 flu vaccine regulatory filings
MRNA is trading at $31.84 (+3.16%) following the announcement of global regulatory submissions for its investigational seasonal influenza vaccine,...
🟢 MRNA is trading 3.16% up today driven by FDA regulatory submissions for mRNA-1010 flu vaccine
MRNA is trading at $31.84 (+3.16%) following the announcement of global regulatory submissions for its investigational seasonal influenza vaccine,...